The very public debate about potential harmful consequences of exposure to the plastic monomer bisphenol A (BPA) is a leading high-profile battleground in a scientific revolution currently under way in toxicology ([@b15-ehp-117-1652]; [@b19-ehp-117-1652]). But much more is under contention than the health risks of one chemical. Data emerging from studies of endocrine-disrupting chemicals (EDCs), such as BPA, that mimic or in numerous ways interfere with hormone action, challenge the central assumption that has guided toxicology for centuries, including today's regulatory apparatus for assessing chemical safety. In so doing, they challenge the methods and the adequacy of chemical exposure safety standards.

Using High-Dose Testing to Predict Low-Dose Effects
===================================================

The core assumption of regulatory toxicology is that experiments using high doses will reveal potential effects of low doses. This is derived from 16th-century dogma but is still typically applied today by federal regulators ([@b34-ehp-117-1652]), although it conflicts directly with well-established principles in endocrinology regarding hormone action. The acceptance of this assumption has profound implications for the assessment of risk to human health posed by EDCs.

The approach of using very high-dose testing to predict consequences of much lower doses that are typically within the range of widespread human exposure emerges from a 16th-century observation by Paracelsus that toxicologists paraphrase as "the dose makes the poison" ([@b8-ehp-117-1652]). Paracelsus' logic holds if and only if a chemical's effects follow a monotonic dose--response curve, in which more of the chemical leads to a greater effect. Monotonicity and nonmonotonicity refer to changes in the slope of the curve describing dose and response. Monotonic curves may be linear or nonlinear, but the slope never reverses from positive to negative or vice versa. The slope of a nonmonotonic curve changes sign, from positive to negative or vice versa. Biologically relevant nonmonotonic curves include "U-shaped" or "inverted-U--shaped" dose--response relationships. When toxicologists began to focus on potential health effects of EDCs, endocrinologists raised questions about the appropriateness of assuming monotonicity as a basis for chemical risk assessments, because nonmonotonicity is a general characteristic of endogenous hormones, hormonally active drugs, and environmental chemicals with hormonal activity.

Indeed, Paracelsus' assumption is directly contradicted by decades of research in endocrinology and clinical medicine showing that hormonally active compounds have dose--response curves in which low doses can cause effects opposite to those at high doses. This issue is so central to hormone action that it is a critical component of determining the dose required for hormonally active drugs. Two well-known examples are Lupron \[used to treat reproductive disorders in women and men ([@b9-ehp-117-1652])\] and tamoxifen \[used to treat breast cancer ([@b17-ehp-117-1652])\], in which low doses stimulate whereas high doses inhibit disease. Specifically, for both of these drugs, a phenomenon known as low-dose "flare" occurs, during which there is stimulation of the response that the drug inhibits when the blood level of the drug reaches the high clinically effective dose range (e.g., for Lupron, testosterone secretion in men with prostate cancer; and for tamoxifen, proliferation of mammary tissue in women with breast cancer).

Nonmonotonic Dose--Response Curves
==================================

Nonmonotonic dose--response curves result from multiple mechanisms. Hormones and hormone-mimicking chemicals act through receptors in target cells. Very low doses can stimulate the production of more receptors (receptor up-regulation), resulting in an increase in responses, whereas higher doses (within the typical toxicologic range of chemical testing) can inhibit receptors (receptor down-regulation), resulting in a decrease in responses ([@b31-ehp-117-1652]). The consequence for gene activity, which is regulated by hormone-mimicking chemicals binding to receptors that amplify very small exposures into very large responses, is that very low doses of these chemicals (in the case of a positively regulated gene) can up-regulate gene expression, whereas at higher doses the same chemicals down-regulate gene expression ([@b7-ehp-117-1652]; [@b16-ehp-117-1652]; [@b28-ehp-117-1652]).

If only one response is being measured, a nonmonotonic dose--response curve is a common finding for EDCs. An additional complication, however, is that when multiple outcomes are examined, qualitatively different outcomes are commonly observed at low and high doses of EDCs. One basis for this is that the suite of genes whose expression is regulated by low doses of endogenous hormones and chemicals that mimic these hormones can be completely different from the genes affected by high doses ([@b7-ehp-117-1652]). As the dose increases, hormones and hormone-mimicking chemicals can bind to receptors for other hormones, referred to as receptor cross-talk. For example, at high doses, endogenous and man-made environmental estrogens begin to interact with androgen and thyroid hormone receptors, producing entirely different effects from those seen at low doses, when only significant binding to estrogen receptors occurs ([@b31-ehp-117-1652]). Furthermore, myriad hormonal feedback mechanisms among the brain, pituitary gland, and hormone-producing organs (e.g., thyroid gland, adrenal glands, ovaries, testes) contribute to the presence of nonmonotonic dose--response curves and qualitatively different responses at low and high doses of EDCs. The consequence is that high doses and low doses differ not just in quantitative effects but also in qualitative impact, especially when responses of whole organisms are considered.

Another consideration is that the effects of EDCs classified as "xenoestrogens" are not identical. As research has progressed into identifying the molecular mechanisms mediating responses, a consensus has emerged that this class of EDCs should be categorized as selective estrogen receptor modulators, to highlight the fact that each can result in a unique array of responses. However, conducting studies that involve comparing activities of different xenoestrogens (or other chemicals that act via similar mechanisms) requires understanding the importance of the doses being used ([@b23-ehp-117-1652]).

EDCs may also act by mechanisms that do not require direct mediation by classical hormone receptors. Nonspecific (non--receptor-mediated) toxicity can occur at high but not low doses. EDCs also exert actions upon synthesis or function of enzymes that may be responsible for the synthesis or degradation of hormones and on coregulatory proteins that interact with receptors and, in the case of neurologic actions, affect neuro-transmitters and their receptors ([@b10-ehp-117-1652]). For example, low doses of atrazine activate aromatase gene activity in zebrafish embryos; this activity can alter sex determination via a rapid signaling system ([@b25-ehp-117-1652]). This concept is important because each of these mechanisms may have a unique dose--response relationship for a particular EDC, adding to the complexity of the overall shape of the dose--response curve for each response.

Of great importance, above the dose at which a hormonally active chemical saturates (occupies virtually all) receptors, any change in response that occurs cannot be caused by a receptor-mediated mechanism, which requires a change in receptor occupancy. Receptors for steroid hormones are ligand-activated transcription factors that require a change in ligand binding to affect the rate of gene transcription. Thus, high-dose experiments cannot be used to predict low-dose results mediated by EDCs binding to hormone receptors and altering receptor-mediated responses at low doses. The current paradigm in regulatory toxicology of only testing a few very high doses of chemicals within a relatively narrow dose range (with the highest dose being the maximum tolerated dose) thus does not serve to predict the hazards posed by low-level exposure to numerous EDCs found in most people in biomonitoring studies conducted in the United States and elsewhere ([@b5-ehp-117-1652]).

Nonmonotonic dose--response curves have been reported for adverse effects with a number of EDCs ([@b18-ehp-117-1652]), including the polycarbonate plastic monomer BPA ([Figure 1](#f1-ehp-117-1652){ref-type="fig"}) used in some baby bottles, water bottles, and food can linings ([@b33-ehp-117-1652]); di(2-ethylhexyl) phthalate (DEHP), used in medical devices and other products made with polyvinyl chloride plastic ([@b27-ehp-117-1652]); and the pesticides dieldrin, endosulfan, and hexachlorobenzene ([@b20-ehp-117-1652]). For example, exposure to DEHP at a concentration 1,000-fold less than the current safety standard, which is based on high-dose liver toxicity, exacerbated allergic reactions ([@b27-ehp-117-1652]). Similarly, exposure to extremely low (picomolar, parts per trillion) levels of several persistent organic pollutants increased allergic responses ([@b20-ehp-117-1652]). None of these effects was predicted by studies that examined only high doses of these chemicals.

In an experiment explicitly designed to test the adequacy of high-dose testing of DEHP in rats, [@b1-ehp-117-1652] found that a high dose increased estrogen-synthesizing (aromatase) enzyme activity in the brains of neonatal male rats; a dose 100-fold lower appeared to be the "no effect dose," which is used to estimate the dose deemed safe for human exposure (the aromatase enzyme is involved in determining sex differences in brain function). Only because the scientists broke with tradition and also tested lower doses did they find significant down-regulation of aromatase at a dose 37 times lower than the putative no effect dose, an effect opposite to and unpredicted from results of testing only very high doses.

Other experiments have documented nonmonotonicity in rat pituitary and cerebellar cortex cells exposed to picomolar through micromolar levels of BPA ([@b35-ehp-117-1652]; [@b36-ehp-117-1652]). Acting through a relatively recently discovered non-classical estrogen response system, very low picomolar concentrations of BPA increased calcium influx and activation of enzyme cascades that dramatically amplify a very low-dose signal into a large cellular response. The dose--response curve followed a nonmonotonic inverted-U shape, with the strongest response at picomolar to low nanomolar levels. The bioactive concentrations of BPA in these experiments were below the range found ubiquitously in human blood and urine. Other end points that follow a nonmonotonic pattern for BPA are human prostate cancer cell proliferation ([Figure 1](#f1-ehp-117-1652){ref-type="fig"}) ([@b33-ehp-117-1652]), promotion of human seminoma cell proliferation ([@b4-ehp-117-1652]), and production of the insulin-response--regulating hormone adiponectin by human adipocytes ([@b12-ehp-117-1652]). These specific responses to BPA occurred within the range of human exposure to BPA based on biomonitoring studies ([@b5-ehp-117-1652]; [@b21-ehp-117-1652]; [@b22-ehp-117-1652]) but were not observed at much higher doses.

Research over the past 20 years has identified multiple EDCs that mimic or disrupt hormone function at low doses in ways that are not predicted by high-dose studies. Biomonitoring studies have established that many of these contaminants are widespread in people. Yet classical regulatory toxicology ignores nonmonotonicity despite the fact that, similar to hormones, EDCs would be expected to display nonmonotonic dose--response patterns for many responses. This disconnect with current science pervades virtually all regulatory agencies responsible for chemical safety around the world, and it means that many regulatory decisions are highly likely to have underestimated risks.

Health Implications
===================

If the health implications of these decisions were inconsequential, the clash between regulatory toxicology and endocrinology would appropriately remain buried in academia. But the range of health conditions now plausibly linked to EDCs---including, but not limited to, prostate cancer ([@b6-ehp-117-1652]), breast cancer ([@b24-ehp-117-1652]), attention deficit hyperactivity disorder ([@b13-ehp-117-1652]), infertility and male and female reproductive disorders ([@b11-ehp-117-1652]; [@b26-ehp-117-1652]), miscarriage, and most recently, hyperallergic diseases, asthma ([@b3-ehp-117-1652]), obesity ([@b12-ehp-117-1652]), and heart disease and type 2 diabetes ([@b14-ehp-117-1652]; [@b30-ehp-117-1652])---makes it imperative that the clash between endocrinology and regulatory toxicology be resolved in ways that reflect modern scientific understanding.

These chronic diseases are major contributors to the steadily increasing human disease burden and to the escalating cost of health care throughout the world. Extensive, careful, and replicable animal research suggests that numerous common man-made chemicals to which people are exposed every day, but that have not been adequately studied for health effects in humans, may be significant contributors to these adverse health trends. Because the endocrine system is highly conserved between animals used as models in biomedical research and humans, the default assumption should be that nonmonotonic dose--responses of EDCs observed in laboratory animals and *in vitro*, including with human cells and tissues, are applicable to human health ([@b12-ehp-117-1652]; [@b32-ehp-117-1652]). Modernizing relevant health standards by incorporating endocrinologic principles could help reduce a significant portion of the human disease burden, but this will require regulatory decision makers to fundamentally change the paradigm commonly used to assess the risk to human health posed by chemicals.

Specific Recommendations and Conclusion
=======================================

We recommend the following:

-   Animal testing protocols used to establish regulatory safety standards must include experiments that examine effects of chemicals over a wide dose range that at their low end overlap with typical human exposures, particularly those experienced by vulnerable populations based on biomonitoring data, or modeling if actual data do not exist.

-   Current scientific knowledge obtained through studies on the endocrine system and its disruption by exogenous chemicals should be applied systematically when regulatory standards on EDCs are to be established. For the best interest of public safety, cooperation of chemical manufacturers in reevaluating safety of their products under the new criteria is critical. Their acceptance of the endocrinology-derived concept that high-dose experiments are insufficient to establish safety standards for EDCs is essential. Continued denial of the reality that nonmonotonic dose--response curves are predicted to occur for EDCs is no longer tenable ([@b2-ehp-117-1652]; [@b29-ehp-117-1652]).

The soaring health care crisis unfolding in countries around the world demands that the regulatory apparatus of governments move into the 21st century. Blind obedience to 16th-century dogma will not solve the problem. Unless and until regulatory agencies incorporate modern endocrinologic principles into their risk assessment paradigms, they will continue to provide false assurances of "safety" and fail to recognize the actual health risks posed by chronic low-level exposure to an increasing number of chemicals found in commonly used products.
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![BPA induces cell proliferation in androgen-independent LNCaP prostate cancer cells. LNCaP cells were propagated for 72 hr in 5% charcoal-/dextran-treated fetal bovine serum supplemented with 0.1% ethanol vehicle and increasing BPA concentrations (0.1--100 nM). Cells were then labeled with bromode-oxyuridine (BrdU), and BrdU incorporation was detected via indirect immunofluorescence. Data shown are mean ± SD of three independent experiments in which at least 250 cells/experiment were analyzed. The shaded region indicates typical concentrations found in humans (Vandenbergh et al. 2007). The response to 100 nM BPA did not differ from control. A standard toxicity test, working down the dose--response curve from high doses, would have shown no difference between controls and exposed animals at a dose at that level or above and would have used it to identify the "apparent no observed adverse effect level (NOAEL)," indicated by the arrow. Testing at lower doses would not have been conducted, and the stimulatory effect of BPA at 1 nM and 10 nM would never have been observed. Figure modified from [@b33-ehp-117-1652].](ehp-117-1652f1){#f1-ehp-117-1652}
